

MEDICAL POLICY

MEDICAL POLICY DETAILS	
Medical Policy Title	Electrical Stimulation as a Treatment for Pain and Other Medical Conditions
Policy Number	01.01.55
Category	Technology Assessment
Original Effective Date	11/21/24
Committee Approval Date	11/21/24
Current Effective Date	11/21/24
Archived Date	N/A
Archive Review Date	N/A
Product Disclaimer	<ul style="list-style-type: none"> Services are contract dependent; if a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including an Essential Plan or Child Health Plus product), medical policy criteria apply to the benefit. If a Medicaid product covers a specific service, and there are no New York State Medicaid guidelines (eMedNY) criteria, medical policy criteria apply to the benefit. If a Medicare product (including Medicare HMO-Dual Special Needs Program (DSNP) product) covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit. If a Medicare HMO-Dual Special Needs Program (DSNP) product DOES NOT cover a specific service, please refer to the Medicaid Product coverage line.

POLICY STATEMENT

I. Transcutaneous Electrical Nerve Stimulation (TENS)

A. The following items are considered **medically necessary**:

1. U.S. Food and Drug Administration (FDA) approved devices including but not limited to the BioniCare Stimulator Model BIO-1000, and H-wave Stimulation when **ALL** the following criteria are met:
 - a. utilized for the treatment of pain;
 - b. symptoms persist for greater than three months;
 - c. failure of physical therapy, osteopathic manipulative therapy, or chiropractic therapy;
 - d. failure of medications (e.g., simple analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs) or opioids); **and**
 - e. 30-day trial period has demonstrated efficacy of the treatment.
2. The U.S. Food and Drug Administration (FDA) approved form-fitting conductive garments utilized for the delivery of TENS when the following criteria are met:
 - a. The criteria in Policy Statement 1 are met;
 - b. The nerve supply to the stimulated area is intact; **and**
 - c. At least **ONE** of the following criteria apply:
 - i. treatment includes a large stimulation area or considerable number of stimulation sites, and the member cannot reasonably manage the treatment without the use of the garment;
 - ii. the stimulation site is not accessible with standard electrodes, adhesive tape or lead wires; **or**
 - iii. skin or other medical condition exists that would prevent the adherence of standard electrodes, tapes or lead wires.

B. TENS is considered **not medically necessary** for the following indications:

1. the relief of pain in labor and vaginal delivery;

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS

Policy Number: 01.01.55

Page: 2 of 23

2. treatment of headaches and/or migraines;
3. visceral abdominal pain;
4. temporomandibular joint (TMJ) disorder;
5. cancer pain;
6. essential tremor;
7. low back pain;
8. neck pain.

C. The following stimulators are considered **investigational** for all indications:

1. Pulsed Electrical Stimulators (PES), including BioniCare when used to facilitate repair of cartilage in patient with arthritis (e.g., SoftPulse, MedRelief ST Series, and Jstim1000);
2. Electromagnetic Stimulators (e.g., OrthoCor Active Knee System, and RS-4i sequential stimulator); **and**
3. Transcutaneous Electrical Joint Stimulation (TEJSD) for the treatment of joint pain associated with arthritis (e.g., HCPCS code E0762).

II. Neuromuscular Electrical Stimulation (NMES)

A. NMES is considered **not medically necessary** for **ALL** of the following indications including but not limited to:

1. treatment of disuse atrophy;
2. lymphedema;
3. tissue damage (e.g., chronic wounds);
4. treatment of motor disorders;
5. cerebral palsy;
6. spina bifida;
7. non-progressive myopathies; **and**
8. treatment of dysphagia.

III. Functional Electrical Stimulation (FES)

A. FES is considered **not medically necessary** for **ALL** of the following indications including but not limited to:

1. for ambulation in patients with spinal cord injury;
2. for stroke rehabilitation; **and**
3. gait training.

IV. The following stimulation devices are considered **investigational** for **ALL** indications:

- A. Peripheral Nerve Stimulation (PNS):
 1. Permanent PNS Systems (e.g., Moventis PNS, StimQ, Nalu);
 2. Temporary PNS System (e.g., SPRINT);
- B. Percutaneous Electrical stimulation (PENS)/Percutaneous Neuromodulation Therapy (PNT);
- C. Restorative Neurostimulation Therapy (e.g., ReActiv8);
- D. Interferential Stimulation (e.g., RS 4i Sequential Stimulator, Empi IF 3Wave);
- E. External Trigeminal Nerve Stimulation (eTNS) (e.g., Monarch);
- F. Transcutaneous Supraorbital Neurostimulation (e.g., Cefaly);
- G. Remote Electrical Neuromodulation (REN) devices (e.g., Nerivio);
- H. Afferent Patterned Stimulation Therapy for Essential Tremor (e.g., Cala One, Cala Trio);
- I. Cranial Electrical Stimulation (e.g., Alpha Stim-AID, Carvella, CES Ultra);
- J. Peripheral Magnetic Stimulation (e.g., Axon Therapy, MagVenture Pain Therapy);
- K. Single Pulse Transcranial Magnetic Stimulation (e.g., SpringTMS) for the treatment of headache/migraine;
- L. Transcutaneous/Non-Implantable Vagus Nerve Stimulation (tvNS);
- M. Devices capable of delivering multiple modalities such as interferential stimulation, electrical stimulation;
- N. Neuromuscular Electrical Stimulation (e.g., TruWave Plus, NexWave, Empi Continuum);
- O. Electromagnetic Transcutaneous Peripheral Nerve Stimulator (Axon Therapy devices) for chronic diabetic neuropathy;
- P. Auricular Electrostimulation (e.g., IB-Stim, NSS-2 Bridge device, P-Stim).

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS

Policy Number: 01.01.55

Page: 3 of 23

- V. Repair and/or replacement of a medically necessary electrical stimulation devices or components not under warranty will be considered **medically appropriate** when the following criteria are met:
- A. Physician documentation includes **ALL** of the following:
1. date of device implantation/initiation; manufacturer warranty information, and
 2. attestation that the patient has been compliant with the use of device, and
 3. will continue to benefit from the use of device;
- AND ONE OF THE FOLLOWING APPLY:**
- B. Repair of the currently used device when **ALL** of the following are met:
1. it is no longer functioning adequately,
 2. inadequate function interferes with activities of daily living, and
 3. repair is expected to make the equipment fully functional (as defined by manufacturer); **OR**
- C. Replacement of the currently used device when the following are met:
1. it is no longer functioning adequately, **AND EITHER**
 2. has been determined to be non-repairable, or
 3. the cost of the repair is in excess of the replacement cost; **OR**
- *D. Replacement of the currently used device when **BOTH** of the following are met:
1. there is documentation that a change in the patient's condition makes the present unit non-functional, and
 2. improvement is expected with a replacement unit.
- VI. The replacement of properly functioning electrical stimulation devices or external components is considered **not medically necessary**. This includes, but is not limited to, replacement desired due to advanced technology or in order to make the device more aesthetically pleasing.
- VII. Repair or replacement of equipment damaged due to patient neglect, theft, abuse, or when another available coverage source is an option (e.g., homeowners, rental, auto, liability insurance, etc.) is **ineligible for coverage**.

Refer to Corporate Medical Policy #1.01.07 Oral Appliance for the Treatment of Obstructive Sleep Apnea

Refer to Corporate Medical Policy #1.01.19 Pelvic Floor Electrical Stimulation as a Treatment for Urinary or Fecal Incontinence

Refer to Corporate Medical Policy #7.01.41 Surgical Management of Sleep Disorders

Refer to Corporate Medical Policy #7.01.05 Vagus Nerve Stimulation and Vagus Nerve Blocking Therapy

Refer to Corporate Medical Policy #3.01.09 Transcranial Magnetic Stimulation

Refer to Corporate Medical Policy #7.01.10 Sacral Nerve Stimulation

Refer to Corporate Medical Policy #8.01.22 Tibial Nerve Stimulation (TNS) for Voiding Dysfunction

Refer to Corporate Medical Policy #11.01.03 Experimental or Investigational Services

POLICY GUIDELINES

- I. Coverage of durable medical equipment is contract dependent unless required under Federal or State mandates.
- II. The use of TENS therapy is a relative contraindication in patients with a pacemaker or an implantable cardioverter defibrillator (ICD). Electrical interference from the TENS unit has been reported and may interfere with the proper functioning of these devices.
- III. The correct CPT code to use for percutaneous electrical nerve stimulation (PENS) and percutaneous neuromodulation therapy (PNT) is the unlisted CPT code 64999. CPT codes for percutaneous implantation of neurostimulator electrodes (i.e., CPT code 64553 to 64561) are not appropriate, because PENS and PNT use percutaneously inserted needles and wires rather than percutaneously implanted electrodes. The stimulation devices used in PENS and PNT are not implanted, so CPT code 64590 is also not appropriate.

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS

Policy Number: 01.01.55

Page: 4 of 23

DESCRIPTION

Electrical stimulation (Estim) is a technique that uses low level electrical currents to stimulate muscles or nerves for therapeutic purposes. These devices and treatments are used in various medical and physical therapy application. The U.S. Food and Drug Administration (FDA) has approved many stimulation devices based on their substantial equivalence to predicate devices. There are devices for both home and clinic use. Altering the frequency, intensity, location and pulse duration of the devices allows them to be marketed individually.

Transcutaneous Electrical Nerve Stimulation (TENS)

TENS is the application of an electrical current through the skin to stimulate the nervous system. The first device was patented by Medtronic Inc and has since been utilized to relieve pain in a portable, noninvasive way. The device delivers mild pulsed electrical currents through electrode pads placed on the surface of the skin. Users can change the frequency, intensity, and pulse duration of the TENS based upon the patient's comfort and response. The intensity of the TENS device can be altered to a comfortable sensation without motor contraction, to the highest level of motor contractions (noxious). Traditional TENS is delivered utilizing high-frequency, low intensities and small pulse durations. Noxious level TENS have been investigated for patients with chronic pain.

TENS for the Treatment of Arthritis

The BionCare Bio-1000 stimulator (VQ OrthoCare) was cleared for marketing by the FDA in 1997 through the 510(k) process to deliver pulsed electrical stimulation for adjunctive treatment of osteoarthritis of the knee and was then later approved for rheumatoid arthritis of the hand. The FDA originally determined that this device was substantially equivalent to TENS devices. In 2006, the FDA reclassified the device as a transcutaneous electrical stimulator for arthritis upon the manufacturer's request given that the target tissue is not nerve, but rather joint tissue. The BionCare System consists of an electronic stimulator device with electrical leads placed over the affected area and is held in place with a lightweight, flexible wrap, and self-adhesive fasteners.

The OrthoCor Active Knee System (OrthoCor Medical; acquired by Caerus Corp) uses pulsed electromagnetic field energy at a radiofrequency of 27.12 MHz to treat pain. In 2009, the OrthoCor Knee System was cleared for marketing by the FDA through the 510(k) process and is classified as a short-wave diathermy device for use other than applying therapeutic deep heat. It is indicated for adjunctive use in the palliative treatment of postoperative pain and edema in superficial soft tissue and for the treatment of muscle and joint aches and pain associated with overexertion, strains, sprains, and arthritis. In 2008, the SofPulse (also called Torino II, 912-M10, and Roma; Ivivi Health Sciences, renamed Amp Orthopedics) was cleared for marketing by the FDA through the 510(k) process as a short-wave diathermy device that applies electromagnetic energy at a radiofrequency of 27.12 MHz. The device is indicated for adjunctive use in the palliative treatment of postoperative pain and edema in superficial soft tissue.

H-wave Stimulation is a form of electrical stimulation that differs from others given its waveform. It emits a prolonged pulse width/duration and can produce effective anesthesia/analgesia without weakness or tetany with extended use such as that which is seen with neuromuscular electrical stimulation. H-wave devices are available for home use as durable medical equipment. H-wave stimulation has been used for pain control, treatment of diabetic neuropathy, muscle sprains, TMJ dysfunctions or reflex sympathetic dystrophy. It has also been used to accelerate healing of wounds (e.g., diabetic ulcers).

Neuromuscular Electrical Stimulation (NMES) /Functional Electrical Stimulation (FES)

NMES is a form of treatment that uses a device that transmits an electrical impulse to activate muscle groups by way of electrodes. NMES is proposed to promote neuromuscular re-education, improve motor unit recruitment, and prevent or diminish muscle atrophy. NMES is typically used as a component of a comprehensive rehabilitation program. Compared to TENS, NMES delivers a stronger current with a wider pulse width. The stimulator device is classified as durable medical equipment. NMES can be referred to as functional electrical stimulation (FES), functional neuromuscular stimulation (FNMS), or electromyography (EMG) triggered neuromuscular stimulation.

Functional electrical stimulation involves the use of an orthotic device or exercise equipment with microprocessor controlled electrical muscular stimulation. FES devices are being developed to restore function and improve health in

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS

Policy Number: 01.01.55

Page: 5 of 23

individuals with damaged or destroyed nerve pathways (e.g., spinal cord injury [SCI], stroke, multiple sclerosis, cerebral palsy). It attempts to replace stimuli from destroyed nerve pathways with computer-controlled sequential electrical stimulation of muscles through surface or implanted electrodes. The goal is to enable patients with spinal cord injury (SCI) or stroke to function independently or at least maintain muscle tone and strength.

Surface or percutaneous devices for upper extremity FES (e.g., H200 Wireless Hand Rehabilitation System) combine a wrist/hand orthosis with integrated surface electrodes to activate muscles of the paralyzed forearm and hand. Upper extremity surface FES devices may be most effective when used soon after spinal cord injury, during the acute phase of rehabilitation.

Threshold electrical stimulation (TES) uses surface electrodes to stimulate the muscle when the patient is in a resting state. It is intended to increase muscle strength and joint mobility, leading to improved voluntary motor function.

Parastep I is a surface FES device intended to allow patients with lower extremity paralysis to stand and walk short distances.

The WalkAide system is a FES device that improves the walking ability of people suffering from foot drop. WalkAide uses sensor technology to analyze the movement of the leg and foot, sending electrical signals to the peroneal nerve which activates the muscles to raise the foot at the appropriate time during the step cycle.

Implanted FES devices (e.g., the Freehand System) devices incorporate surgically implanted stimulation electrodes, an implanted stimulator, and an external power supply. A shoulder position sensor mounted on the chest and shoulder translates small shoulder movements into a control signal. Use of these devices requires intensive and lengthy training by rehabilitation specialists.

MicroVas is a noninvasive electrical stimulator that causes muscles contraction and relaxation cycles. It is used to treat small vessel disease and neuropathy in the feet and ankles. The MicroVas stimulator is supposed to increase blood flow, tissue oxygenation, promote lymphatic drainage, and induce involuntary exercise. However, it has not been proven for this purpose. MicroVas therapy was developed originally by the U.S. Military to treat hypothermia in Navy Seals.

VitalStim Therapy is a type of neuromuscular electrical stimulation in which a small current is passed through external electrodes placed on the neck to stimulate inactive or atrophied swallowing muscles. With repeated therapy, throat muscles are reported to be re-trained, and the patient progresses to an optimum level of swallow function.

Functional Electrical Stimulation Devices cleared by the FDA (not an all-inclusive list)

Device	Manufacturer	Device Type	Date
NESS H200 (previously Handmaster)	Bioness	Hand Stimulator	2001
MyndMove System	MyndTec	Hand Stimulator	2017
WalkAide System	Innovative Neurotronics (formerly NeuroMotion)	Foot drop stimulator	2005
L100 Go	Bioness	Foot drop stimulator	2020
EvoWalk 1.0	Evolution Devices Inc	Foot drop stimulator	2023
ERGYS (TTI Rehabilitation Gym)	Therapeutic Alliances	Leg cycle ergometer	1984
Myocycle Home	Myolyn	Cycle ergometer	2017

Peripheral Nerve Stimulation (PNS)

PNS is a similar concept to TENS but different in that electrodes are implanted around or adjacent to the nerve serving the painful stimuli and then stimulated using a pulse generator and remote control. A trial of treatment is typically required

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS

Policy Number: 01.01.55

Page: 6 of 23

prior to permanent implant of the generator and/or electrodes. Success of the trial is defined as >50% reduction in pain response. PNS is generally reserved for patients who fail to get pain relief from TENS, medications, physical therapy or injection therapy.

The Moventis PNS (Micron Medical Corporation) received FDA approval in May 2020 based upon substantial equivalence to The Freedom Spinal Cord Stimulator (SCS) System (Curonix) and an implanted peripheral nerve stimulator (StimQ PNS, Stimwave Technologies) for pain management. All of the devices are intended to treat adults who have severe intractable chronic pain of peripheral origin, as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach and are not intended to treat pain in the craniofacial region of the body.

The Nalu neurostimulation (Nalu Medical, Inc.) system was cleared by the FDA as both a SCS and PNS in June 2020. Nalu peripheral nerve stimulation involves a 3-step process: wear experience, therapy trial, and permanent implantation. The treatment involves the initial use of adhesive clips and nonfunctioning Therapy Discs to determine future stimulation location and comfort level, followed by a temporary trial of the implanted leads, prior to permanent implantation. It is used for the management of chronic pain.

The SPRINT peripheral nerve stimulation system (SPR Therapeutics, Inc.) received FDA clearance in 2017. Considered a temporary device, SPRINT uses a percutaneous electrode placed via an introducer needle near target peripheral motor or sensory nerves. The insertion of the implant does not require incisions or anesthesia and the indwelling leads are left in place for up to 60 days. The device utilizes 300-micron diameter leads (one quarter the size of conventional neurostimulation leads) to provide a safe lead withdrawal at the completion of the treatment. The device is intended to provide symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain. It is not intended to treat pain in the craniofacial region of the body.

Percutaneous Electrical Nerve Stimulation (PENS)/Percutaneous Neuromodulation Therapy (PNT)

PENS and PNT are terms often used interchangeably in the literature. This form of stimulation utilizes very fine needle-like electrode arrays placed near the painful area to stimulate peripheral sensory nerves in the soft tissue. PENS and PNT are also not to be confused with acupuncture using electrical stimulation. In electrical acupuncture, needle electrodes are inserted below the skin, but not necessarily at the site of pain. They are placed according to acupuncture meridians, which are a concept of Chinese medicine.

Restorative Neurostimulation Therapy

In 2020, the ReActiv8 (Mainstay Medical) device was FDA approved through the Premarket Approval (PMA) process (PMA P190021) and is a permanent implant indicated for adults with intractable chronic low back pain associated with multifidus dysfunction who have failed pain medications and physical therapy and are not candidates for spine surgery. The device components consist of an implantable pulse generator, stimulation leads, software and programmer wand, activator and magnet. ReActiv8 is marketed as the first and only restorative neurostimulation therapy to treat mechanical chronic low back pain and is full body MRI conditional.

Interferential Stimulation (IFS)

IFS is an anti-inflammatory based treatment modality. The interferential stimulator crosses two medium frequency alternating currents, which penetrate deep into soft tissue. It is intended for use in the treatment of circulation disorders, range of motion issues, edema and muscle spasms. It is reported to stimulate bone healing, inhibit pain and promote soft tissue healing. A number of interferential stimulator devices have received FDA approval including the Medstar 100 (Mednet Services and the RS-4V (RS Medical).

External Trigeminal Nerve Stimulation (eTNS)

The Monarch eTNS system, (NeuroSigma) was approved by the FDA on April 19, 2019 through the De Novo process and classified as a transcutaneous electrical nerve stimulator for attention deficit hyperactive disorder device type. It is designed to generate and deliver electrical pulses to the trigeminal nerve, which directs signals to the parts of the brain that are believed to be associated with ADHD. The device is connected to a small patch that adheres to a patient's forehead. It is meant for at-home use during sleep and requires caregiver supervision.

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS

Policy Number: 01.01.55

Page: 7 of 23

Transcutaneous Supraorbital Neurostimulation

The Cefaly device (CEFALY Technology) received FDA approval on March 11, 2014 for the prophylactic treatment of migraines in patients ages 18 years and older. Cefaly is a small, portable, battery-powered, prescription device that resembles a plastic headband worn across the forehead and atop the ears. The user positions the device in the center of the forehead, just above the eyes, using a self-adhesive electrode. The device applies an electric current to the skin and underlying body tissues to stimulate branches of the trigeminal nerve, which has been associated with migraine headaches. The user may feel a tingling or massaging sensation where the electrode is applied. The device should only be worn daily for 20 minutes.

Remote Electrical Neuromodulation (REN)

REN is a nonpharmacologic abortive treatment of migraine. The Nerivio device (Theranica) was cleared by the FDA for patients aged 12 years and above. It is a wireless stimulation device applied to the lateral upper arm in 45-minute sessions and triggers weak electrical impulses to start conditioned pain modulation, a proprietary electrical signal to stimulate noxious sensory fibers and relieve acute migraine. It is controlled by a mobile app that includes a migraine diary to track migraine headaches and treatment sessions. Each device functions for 12 treatments after which, it is to-be disposed of and a new device is required.

Afferent Patterned Stimulation Therapy for Essential Tremor

The Cala Trio (Cala Health) is an external upper limb tremor stimulator. It received FDA approval October 5, 2021. It is a hand-specific device indicated to relieve tremors in adults with essential tremor. The device is worn like a wristwatch. Electrodes embedded into a disposable cloth band deliver stimulation to the median and radial nerves of the wrist after being calibrated to the specific motion of the user. The digital display provides prompts, time, offers the ability to adjust intensity and notifies the user when the band requires changing. The contained accelerometer measures the tremor and adjusts simulation. Sessions are for 40-minutes, and the device is recommended to be used twice daily prior to activities requiring use of that hand.

Cranial Electrical Stimulation (CES)

CES is also known as cranial electrotherapy, transcranial electrical stimulation or electrical stimulation therapy. The most common CES device in the United States, is the Alpha Stim products.

Alpha Stim-AID, and Alpha-Stim M is a handheld prescription device that delivers an electronic microcurrent through electrodes placed further from the brain (i.e., earlobes, scalp, eyelids) and delivers a pulsed, low-intensity current to stimulate specific groups of nerve cells. Although the exact mechanism of action is unknown, CES has been approved by the FDA for the treatment of insomnia, depression, and anxiety. The user can select the level of stimulation and increase or reduce as needed, typically for 20- minute sessions. CES is being evaluated for a variety of other conditions including pain, and functional constipation.

Peripheral Magnetic Stimulation (PMS)

Peripheral magnetic stimulation (PMS), or transcutaneous magnetic stimulation, is a non-invasive method of delivering a rapidly pulsed, high-intensity magnetic field to the periphery other than the brain.

Axon Therapy (NeuraLace Medical, Inc.) was the first FDA approved peripheral magnetic stimulation device. The device received FDA approval through the Section 501(k) premarket approval process in May 2021. Axon therapy utilizes a figure-8 shaped coil to deliver focused magnetic pulses to damage A-Beta sensory nerve fibers during a 13-minute treatment and is intended to simulate peripheral nerves for the relief of chronic intractable, post-traumatic and post-surgical pain for patients 18 years and older.

MagVenture Pain Therapy devices (Tonika Elektronik A/S) were approved in August of 2023 and intended for use in the hospital and clinics.

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS

Policy Number: 01.01.55

Page: 8 of 23

Single-Pulse Transcranial Magnetic Stimulation (sTMS)

sTMS is a non-invasive technique that applies a brief magnetic pulse to the scalp and underlying cortex, changing the pattern of neuronal firing.

The SpringTMS (eNeura Therapeutics, LLC) received FDA approval through the 510 (k) notification process. It is a handheld device positioned on the occipital bone on the back of the head. The user presses a button to deliver a single magnetic pulse of 0.9T, generating an electrical current that causes electromagnetic induction of neurons over the target area. The device is indicated for the treatment of acute pain associated with migraine headache with aura.

Transcutaneous/Non-Implantable Vagus Nerve Stimulation (tVNS)

tVNS is a medical treatment that involves delivering electrical impulses to the auricular or cervical branch of the vagus nerve. It has been proposed as an adjunctive treatment for certain types of treatment-resistant depression, tinnitus, diabetes, endotoxemia, memory, myocardial infarction, headache, pain, intractable epilepsy, and stroke.

In May 2017, the gammaCore-S (electroCore LLC), a noninvasive vagus nerve stimulation device, was cleared for marketing through the Section 510(k) process for the acute treatment of adults with episodic cluster headaches. When the device is applied to the side of the neck by the patient, a mild electrical stimulation of the vagus nerve is carried to the central nervous system. Each stimulation using gammaCore-S lasts two minutes. The patient controls the stimulation strength. In 2021, the gamma-Core Sapphire received FDA approval for the pre-market notification intent as a substantiated equivalent to the predicate device, with additional indications for use including the preventative treatment of migraine headache in adolescent (age 12 and older) and adult patients, the acute treatment of pain associated with migraine headache in adolescent (age 12 and older) and adult patients, and for the adjunctive use for the preventative treatment of cluster headache in adults.

Multimodal Electrotherapy Stimulation Devices

Combination transcutaneous electrical nerve stimulation, interferential stimulation and neuromuscular electrical stimulation devices are TENS devices capable of delivering any of the three modalities depending on electrode arrangement on the body and programming options. This type of device is intended to treat a wide variety of symptoms especially for acute and chronic pain relief. The TruWave Plus, NexWave, and Empi Continuum are examples of combination devices.

Auricular Electrostimulation

Electrical stimulation of auricular acupuncture points, or auricular electrostimulation, involves the stimulation of acupuncture points on the ear. Auricular electrostimulation has been proposed for the treatment of a variety of conditions, including pain, depression, and anxiety. Devices have been developed that provide electrical stimulation to auricular acupuncture sites over a period of several days.

The P-Stim (NeuroScience Therapy Corporation) is a single-use, miniature electrical stimulator for auricular acupuncture points that is worn behind the ear with a self-adhesive electrode patch. A selection stylus that measures electrical resistance is used to identify three auricular acupuncture points. The P-Stim device connects to three inserted acupuncture needles with caps and wires. The device is pre-programmed to be on for 180 minutes, then off for 180 minutes. The maximum battery life of this single-use device is 96 hours. The P-Stim received U.S. Food and Drug Administration (FDA) marketing clearance through the 510(k) process in 2006.

The E-pulse, or Electro Acupuncture device, is a microprocessor-controlled, battery-powered unit designed to administer auricular point nerve stimulation treatment for pain therapy over a 96-hour period. The E-pulse received FDA 510(k) marketing clearance in 2009.

Auricular PENFS is a variation of PENS in that it uses a low-frequency electrical current to stimulate the skin and underlying tissues in a general area of pain rather than targeting a specific nerve. PENFS devices are thought to work by sending electrical stimulation of peripheral cranial neurovascular bundles in the external ear to help modulate central pain pathways, however, the exact mechanism responsible for the analgesic effects remains unknown. PENFS involves a

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS

Policy Number: 01.01.55

Page: 9 of 23

nonimplantable device that stimulates nerves remotely from the site of pain and has been studied for a variety of musculoskeletal and neuropathic pain conditions, and patients with opioid withdrawal.

The NSS-2 Bridge device (Innovative Health Solutions, Inc.) is a small electrical nerve stimulator placed behind the ear that emits electrical pulses to stimulate branches of certain cranial nerves, which may provide relief from opioid withdrawal symptoms. The FDA cleared this device in 2017 through the de novo premarket review pathway for use in reducing the symptoms of opioid withdrawal.

The IB-Stim (Innovative Health Solutions, Inc.) is a disposable, battery-powered, percutaneous electrical nerve field stimulator (PENFS) system placed behind the ear. The FDA cleared the IB Stim device through de novo premarket. The device has four percutaneously placed electrodes (three frontal and one dorsal) applied to auricular areas innervated by branches of four cranial nerves (CN V, VII, IX, and X). It is intended use are for patients 11-18 years old with functional abdominal pain disorders (FAPD) associated with irritable bowel syndrome (IBS). The device is for use 120 hours per week for three consecutive weeks.

RATIONALE

Transcutaneous Electrical Nerve Stimulation and H-Wave Stimulation

TENS and H-Wave Muscle Stimulators have a treatment effect beyond that of a credible placebo. Their use may be justified in those individuals with mild acute or chronic pain who wish to use a nonpharmacological form of analgesia. An abstract of 101 patients presented at the 2004 annual meeting of the American Academy of Orthopedic Surgeons reported that 50% of patients avoided total knee arthroplasty by using the BioniCare system. However, there was no randomly assigned control group in this abstract. The FDA classified this device as a TENS unit, however, the manufacturer has indicated that it is a new category of device, as it uses a different array of proprietary electrical amplitudes than a TENS unit and does not function to stimulate nerves. Instead, the BioniCare device is purported to stimulate chondrogenesis. However, no studies have been performed to evaluate whether chondrogenesis occurs with use of this device.

Centers for Medicare & Medicaid Services (CMS) has posted a Decision Memo for Transcutaneous Electrical Nerve Stimulation for Chronic Low Back Pain. Chronic low back pain is defined as an episode of low back pain that has persisted for three months or longer that is not a manifestation of a clearly defined and generally recognizable primary disease entity (e.g., cancers that, through metastatic spread to the spine or pelvis, may elicit pain in the lower back as a symptom; and certain diseases such as rheumatoid arthritis and multiple sclerosis manifest many debilitating symptoms of which low back pain is not the primary focus). The Decision Memo states that TENS is not reasonable and necessary for the treatment of chronic low back pain. In order to support additional research on the use of TENS for chronic low back pain, CMS will cover TENS when the member is enrolled in an approved clinical study meeting all of the requirements listed in the Decision Memo. Case reports have indicated that a TENS has been known to interfere with pacemakers and implantable cardioverter defibrillators (ICDs).

According to the AHRQ Comparative Effectiveness publication on Non-Invasive Treatments for Low Back Pain (2016), additional evidence demonstrates that TENS is not effective versus sham TENS. Effectiveness of TENS was previously classified as insufficient, and the strength of evidence remains low because of methodological limitations in the trials and imprecision. Evidence on harms associated with TENS was limited, but suggests an increased risk of skin site irritation without an increased risk of serious adverse events (AHRQ, 2016). According to the American College of Physician's Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain clinical practice guideline (2017), evidence was insufficient to determine the effectiveness of transcutaneous electrical nerve stimulation (TENS).

Peripheral Nerve Stimulation

The American Society of Pain and Neuroscience developed clinical guidelines for the use of implantable peripheral nerve stimulation in the treatment of chronic pain (2022). Through a systematic review process, 20 randomized controlled trials and 33 prospective observational studies were reviewed. The authors identify that the literature pertaining to PNS neuromodulation is in its initial stages. The goal of the assessment conducted was to fill gaps of current knowledge with the consensus opinions of an expert panel. The authors report that literature supports the efficacy of PNS for the treatment of chronic migraine headaches, chronic hemiplegic shoulder pain, failed back surgery syndrome, and lower extremity

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS

Policy Number: 01.01.55

Page: 10 of 23

neuropathic and post-amputation pain, graded at a IB level of evidence. The authors identified that further robust clinical studies identifying specific conditions, waveforms, programming and lead placements are necessary to ensure standardization of patient and treatment selection.

The North American Spine Society released clinical guidelines for multidisciplinary spine care in the diagnosis and treatment of low back pain in 2020. In response to a question on the effectiveness of electrical stimulation for decreasing the duration of pain, decreasing intensity of pain, increasing functional outcomes and improving return to work status, when compared to natural history plus or minus medication, the authors state “A systematic review of the literature yielded no studies to adequately address this question.”

Percutaneous Electrical Stimulators (PENS) and Percutaneous Neuromodulation Therapy (PNT)

PENS and PNT have been investigated for the treatment of headache, diabetic neuropathy, chronic neck pain, chronic low back pain, chronic surface hyperalgesia, and musculoskeletal pain. A systematic review conducted by Plaza-Manzano and colleagues (2020) concluded that PENS could decrease the level of pain intensity, but not related disability, in musculoskeletal pain disorders. The overall level of evidence, however, was low and there was heterogeneity in the application methods.

Beltran-Alacreu et al. (2022) evaluated the effectiveness of PENS compared to TENS on the reduction of musculoskeletal pain. This systematic review and meta-analysis included a total of nine RCTs in the qualitative analysis, with seven in the quantitative analysis. Overall, there was low-quality evidence for increased pain intensity reduction with PENS over TENS, but the difference found was not deemed to be clinically significant. When only studies with low risk of bias were meta-analyzed, there was a moderate quality of evidence that there is no difference between TENS and PENS for pain intensity. Six out of the nine studies presented high risk for the blinding of participants, and seven out of nine were high risk for blinding of personnel. Beyond these two items, the risk of bias in the included trials was either low or unclear. Protocols and parameters for the application of PENS and TENS were heterogenous across all trials, leading to the conclusion that there is still high uncertainty regarding the effectiveness of PENS for musculoskeletal pain.

Gilmore and colleagues (2021) performed a prospective multi-center study aimed at characterizing the responses of percutaneous medial branch peripheral nerve stimulation (PNS) to see if results from earlier, smaller single-center studies and reports were generalizable when performed on a larger number of patients refractory to nonsurgical treatments. Participants (n=89) with chronic lower axial backpain, a pain score greater than or equal to four, had failed at least two different categories of treatments and had at least four weeks of stable analgesic medication usage were enrolled, eight of which were later to be found ineligible because they did not meet the predefined criteria at the baseline. The target sample size to obtain a 95% confidence interval for the primary endpoint was 90. Authors report enrollment stopped short due to COVID-19. Exclusions included history of lumbar surgery, however, 10 of the patients with a history of lumbar surgery were included as part of a prospectively designed substudy with revised exclusion criteria. Participants were implanted with percutaneous PNS leads from the SPRINT PNS System under ultrasound and/or fluoroscopic guidance and were left in place for up to 60-days, when leads were removed. Follow up was planned for 12 months after the two-month PNS treatment. The study was not completed, and follow-up beyond 8 months is on-going. Clinically and statistically significant reductions in pain intensity, disability, and pain interference were reported by a majority of participants. 73% of participants were successes for the primary end point, reporting clinically significant ($\geq 30\%$) reductions in back pain intensity after the 2-month percutaneous PNS treatment (n = 54/74). Whereas prospective follow-up is ongoing, among those who had already completed the long-term follow-up visits (n = 51), reductions in pain intensity, disability, and pain interference were sustained in a majority of participants through 14 months after the start of treatment. Limitations of the study include lack of randomization and control group.

There are no well-designed randomized controlled studies in the medical literature comparing PNS to established treatment options or a sham procedure; and studies on larger populations with longer follow-up are needed to permit scientific conclusions regarding the benefit and improved health outcomes for the use of PNS.

Neuromuscular Electrical Stimulation

A number of neuromuscular stimulators for therapeutic electrical stimulation have received U.S. Food and Drug Administration (FDA) approval. There is insufficient evidence in the peer reviewed literature to conclude that

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS

Policy Number: 01.01.55

Page: 11 of 23

neuromuscular stimulation is as beneficial as other forms of treatment for disuse atrophy, scoliosis, stroke rehabilitation lymphedema, chronic wounds, or prevention of complications related to musculoskeletal or circulatory impairment after spinal cord injury. Randomized, controlled trials do not demonstrate that neuromuscular stimulation improves motor function in children with cerebral palsy.

Several functional electrical stimulation devices have received FDA approval, including the Parastep I, the Neuro Control Freehand System, the Ness H200 Hand Rehabilitation System, the Ness L300 Foot Drop System, G. Estim FES, and the WalkAide System. There is insufficient data to demonstrate that FES results in improved net health outcomes. Data is insufficient regarding whether patients remain compliant and committed with long-term use of the devices.

No published studies of the MicroVas device were identified. Micro Vas therapy has been around since the late 1980s. It was originally used to treat hypothermia in Navy Seals who experienced the negative effects of extreme temperatures. Over time, Micro Vas therapy evolved into a treatment for neuropathy and other painful conditions, especially those that affect the extremities.

To date, there have been very few studies of surface electrical stimulation to the neck for swallowing that support the efficacy of VitalStim. These studies have small sample size and report mixed results. There is insufficient evidence in the peer reviewed literature to conclude that electrical stimulation is effective in the treatment of dysphagia. Stimulators have not been studied in pregnant women or patients with seizures and balance disorders.

Restorative Neurostimulation Therapy

The FDA approval of the ReActiv8 system was based on a 2020 randomized control trial by Gilligan and colleagues (ReActiv8-B, NCT02577354). The authors have since published two-year and three-year durability studies on the same participants (Gilligan et al 2021, 2023). The pivotal trial was a multicenter sham controlled RCT enrolling 204 individuals with chronic, refractory low back pain. All participants were permanently implanted with the system. Therapeutic group participants (n=102) received active treatment of the medial branch of the dorsal ramus nerve for 30-minutes twice daily. The control group (n=102) received low level sham stimulation. The primary endpoint was the difference in proportions of responders in the treatment and control groups. Response was defined as having a 30% or greater reduction in visual analog scale (VAS) and no increase in pain medications, assessed at 120 days. Following the 120-day randomized phase, participants in the control group were given the option to cross over to the intervention group and were followed along with the participants from the intervention group for up to three years. At 120 days, there was no difference between groups on the primary endpoint of treatment response (57.1% intervention vs 46.6% sham; $p = .1377$) or the individual components of the primary endpoint.

The study investigators conducted prespecified secondary analyses of the primary outcome data, including the between-group difference in VAS at 120 days, a review of participants with increased pain medications, and a cumulative-proportion-of-responders analysis, which graphically displays the proportion of responders across the range of all possible cutoffs and is described as having greater statistical power than the comparison of proportions of the dichotomized primary outcome. The VAS mean change from baseline to 120 days favored the intervention group (-3.3 vs -2.4; $p = .032$), but it is unclear if the difference between groups (0.9 points) was clinically meaningful. The cumulative proportion-of-responders analysis similarly favored the intervention group ($p = .0499$). Nine participants in both the intervention and control groups had an increase in pain medication at 120 days, but the increase was unrelated to low back pain in 6 of 9 participants in the treatment group versus 0 of 9 in the control group. Most importantly, the controlled phase was only 120 days. In the longer-term, uncontrolled follow-up phase of the trial, there was continued improvement in VAS scores over time in those who were assessed. Data was available for 176 of 204 participants at 1 year (86.3%), 156 of 204 participants (79%) at two years, and 130 of 204 (63.7%) at three years. The limitations of the studies, including a lack of a control group and high attrition limits drawing conclusions from these results. Additional evidence from longer-term sham controlled RCTs is needed.

Inferential Stimulation

Hussien et al. (2021) included 19 trials in a meta-analysis of patients (N=1167) to analyze the efficacy of IFS in alleviating musculoskeletal pain. Two trials compared IFS with placebo and the pooled mean difference in pain was significantly reduced with IFS versus a placebo (-0.98; 95% confidence interval [CI], -1.42 to -0.54; $p < .0001$), but this

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS

Policy Number: 01.01.55

Page: 12 of 23

was not demonstrated in the six (6) trials comparing IFS to other interventions (-0.04; 95% CI, -0.20 to 0.12; $p < .65$). When used as an adjunct to other pain interventions, IFS did not significantly improve pain compared with placebo in four (4) studies (-0.06; 95% CI, -0.6 to 0.48; $p = .82$) or compared with active treatment in eight (8) studies (0.02; 95% CI, -0.88 to 0.92; $p =$ not reported). The authors concluded that IFS reduced musculoskeletal pain when used as a single agent compared with placebo, but this is limited by the small number of trials ($n = 2$) and patients enrolled.

External Trigeminal Nerve Stimulation (eTNS)

McCough et al. (2019) assessed the efficacy and safety of TENS in a double-blind, sham-controlled pilot study of pediatric patients with attention deficit hyperactivity disorder (ADHD). The study was a four-week trial followed by one blinded week without intervention. Clinical assessments included weekly clinician-administered ADHD-Rating and Clinical Global Impression (CGI) scales, and quantitative electroencephalography (EEG) at baseline as well as at week four. The primary outcome measure was the clinician completed ADHD-Rating Scale total score. Results revealed that ADHD-Rating Scale totals showed significant group-by-time interactions, demonstrating a differential treatment effect ($F = 8.12$; $df = 1/228$; $p = .005$). The CGI-Improvement scale also favored active treatment over sham ($p = .003$). Quantitative EEG readings were obtained in both groups but there were no participant specific correlations to other outcomes. No serious adverse events were observed in either group and no patient withdrew from the study due to adverse events. Significant increases in weight and pulse were seen with active TENS over the trial period; however, no differences between active and sham TENS with regard to blood pressure were seen. Conclusions were that TENS therapy is efficacious and well-tolerated in pediatric patients with ADHD. Limitations cited were the small sample size and relatively short duration of treatment and follow-up.

Transcutaneous Supraorbital Neurostimulation

The peer-reviewed literature concerning the use of transcutaneous supraorbital neurostimulators for the treatment of migraine headaches consists of results from the Prevention of Migraine (PREMICE) trial of 67 patients randomized to receive the Cefaly device or sham treatment daily for 20 minutes for three months. After the first month of treatment both the treatment and sham groups showed a decrease in migraine days by an average of 20%. This decrease disappeared in the sham group by the second and third month but continued in the treatment group. The 50% responder rate was greater in the treatment group, and the therapeutic gain of effective stimulation over sham was 26%. The monthly attack frequency from the first to the third month was reduced by 18.8% in the treatment group and by only 3.5% in the sham group. Headache severity and the monthly intake of anti-migraine medications was also reduced in the treatment group. No adverse events or side effects were found for either the treatment or sham group. Compliance was moderately satisfactory in both groups. The responder rate for electrical stimulation was within the range of those reported for other migraine treatment modalities. However, the study size was small, and the individuals in the selected cohort were not severely disabled by their migraines.

Remote Electrical Neuromodulation

The FDA market authorization for Nerivio was based on a vendor-funded double blind RCT from Yarnitsky, et al. (2019) involving 252 patients at 12 different sites who met the international classification of headache disorders criteria for migraine, had two to eight migraines per month and less than 12 headache days per year. The authors aimed to evaluate the efficacy and safety of REN for the acute treatment of migraine. Treatment sessions with the device were 45 minutes. Pain relief was defined as improvement from severe or moderate pain to mild or none, or improvement from mild pain to none, of which 66.7% of the active treatment group achieved pain relief at 2 hours post-treatment compared to 38% in sham group. Sustained relief (48 hours post treatment) was achieved by 39% of the treatment group, and in 16% of the sham group. Adverse events were mild and rare. The authors report that the findings are equivalent to migraine relief found with triptan use. The approval of Nerivio for adolescents was based on a study by Hershey and colleagues (2020), a vendor-funded single-arm multicenter study of 39 patients with migraine between the ages of from the ages of 12 and 17. Pain relief at 2 hours was achieved by 71% (28/39) of the patients, and 35% (14/39) were pain free within 2 hours. Study enrollment was shortened to 60% of the planned target due to the coronavirus pandemic however since pain relief at 2 hours was achieved by more than 60% it was determined to be complete. Of those that had pain relief and pain freedom, 90% had sustained relief or freedom for 24 hours. Additional symptoms of nausea, photophobia and phonophobia disappeared at 2 hours in 54%, 41% and 40% of treated individuals. There were mild and low device related adverse

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS

Policy Number: 01.01.55

Page: 13 of 23

events for both of the studies. The writers concluded that Nerivio is both safe and effective for the treatment of acute migraine in adolescents. Longer and larger RCTs with relevant comparators are needed to determine if results can be replicated in other populations, and if the treatment is superior to the current standard of care.

Afferent Pattern Stimulation

Pahwah et al. (2019) studied the use of a novel peripheral (radial and median nerves) stimulation device for the treatment of essential tremor via a RCT of 77 patients and compared to sham stimulation. Although the primary endpoint (an improvement in the Tremor Research Group Essential Tremor Rating Assessment Scale (TETRAS) Archimedes spiral scores) was not met, the authors noted significant improvements in some subject-rated tasks in activities of daily living and clinical global impression-improvement (CGI-I) rating after stimulation. The outcomes were similar to the ranges of improvement offered by standard medications utilized for the treatment of tremor. The authors concluded that peripheral nerve stimulation may provide a safe, well-tolerated, and effective treatment for transient relief of hand tremor symptoms, however future studies over time and multiple sessions are needed.

Isaacson et al. (2020) evaluated the repeated home use of an FDA-cleared wrist-worn neuromodulation device in the Prospective Study for Symptomatic Relief of Essential Tremor with Cala Therapy (PROSPECT) trial. For each active treatment session, the device electrically stimulated the median and radial nerves for 40 minutes with an alternating burst pattern tuned to the frequency of each patient's tremor. The pre-specified co-primary endpoints were improvements on the clinician-rated Tremor Research Group Essential Tremor Rating Assessment Scale (TETRAS) and patient-rated Bain & Findley Activities of Daily Living (BF-ADL) dominant hand scores. Of the 263 enrolled patients, 205 completed the visit three follow-up and were included in the primary analysis. Results revealed a significant improvement in TETRAS and BF-ADL from pre- to post-stimulation at each clinic visit ($p < .0001$ for all comparisons). Pre-stimulation tremor levels were improved from Visit 1 to 3 on both TETRAS and BF-ADL ($p < .0001$ for both). Patients rated as "severe" or "moderate" improved with both TETRAS (49.3% at baseline to 21% at study exit) and BF-ADL (64.8% at baseline to 23% at study exit) scoring. Tremor power is a calculation of amplitude and frequency. Tremor power decreases with lower amplitude motions and lower frequency motions. Tremor power was also noted to significantly improve with therapy from pre- to post-stimulation ($p < .0001$). No device-related serious adverse events were reported. Non-serious device related adverse events occurred in 18% of patients (e.g., persistent skin irritation, sore/lesion, discomfort, electrical burns, and minor skin irritation). Conclusions were that the repeated in home use of this neuromodulation device over three months was effective and safe for patients with essential tremor. Limitations identified were the open-label, single-arm design, the lack of consensus for the definition of clinically meaningful improvement in TETRAS or BF-ADL, as well as the exclusion of 58 patients who exited the study early from the pre-specified primary and secondary endpoint analyses.

Cranial Electrical Stimulation (CES)

CES has been investigated for individuals with headache, chronic pain, depression, and Parkinson disease. Trials that studied headache found only marginal benefits. Trials studied for chronic pain did not show a benefit. The evidence for the use of CES for psychiatric, behavioral, or neurologic conditions include a systematic review and a number of small sham controlled RCTs, only one of which (Barclay et al, 2014) found a significant benefit for its use in depression, but the sample size was small with strong potential placebo effects. Additionally, studies had significant heterogeneity in study populations and treatment protocols.

Ahn et al. (2020) published a double-blind, randomized, sham-controlled pilot study of the feasibility and efficacy of remotely supervised CES via secure videoconferencing in 30 older adults with chronic pain due to knee osteoarthritis. Mean age was 59.43 years. CES was delivered via the Alpha-Stim M Stimulator, which was preset at 0.1 mA at a frequency of 0.5 Hz, and applied for one hour daily on weekdays for two weeks. The sham electrodes were identical in appearance and placement, but the stimulator did not deliver electrical current. The study was conducted in a single center in Houston. All 30 participants completed the study and were included in the outcome analyses. For the primary outcome of clinical pain at two weeks as assessed by a Numeric Rating Scale, a significantly greater reduction occurred in the active CES group (-17.00 vs. +5.73; $p < .01$). No patients reported any adverse effects. Important relevancy limitations include lack of assessment of important health outcomes or long-term efficacy. An important conduct and design limitation is that it is unclear how convincing the sham procedure was as it did not involve any feature designed to simulate a tingling sensation and give the patient the feeling of being treated (i.e., subtherapeutic amplitude, initial current

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS

Policy Number: 01.01.55

Page: 14 of 23

slowly turned to zero). Therefore, findings may be subject to the placebo effect. This trial was also limited by the small number of participants. These limitations preclude drawing conclusions based on these findings.

Wu et al. (2020) published a double-blind, randomized, sham-controlled trial of the efficacy and safety of CES as an add-on treatment for tic disorders in 62 children and adolescents who lacked a clinical response to prior treatment of four weeks of pharmacotherapy. Cranial electrotherapy stimulation was delivered via the CES Ultra stimulator (American Neuro Fitness LLC) at 500 μ A-mA and applied for 30 minutes daily on weekdays for 40 days. The sham CES was delivered at lower than 100 μ A. The study was conducted at a single academic medical center in China. A total of nine participants (14.5%) discontinued the intervention early and were excluded from the analyses. There was no significant difference between the active CES and sham groups in the change in Yale Global Tic Severity Scale (YGTSS) score (-31.66% vs. 23.96%; $p=.13$).

Kim et al. (2021) reported on a three-week randomized, double-blind, sham-controlled trial evaluating the effectiveness of home-based CES ($n=25$) versus sham treatment ($n=29$) in nonclinical patients with daily anxiety. Novel, headphone-like, in-ear electrodes were used in this study. Results demonstrated a significant reduction in anxiety scores using the State Anxiety Inventory (SAI) with CES versus sham stimulation treatment. Depression inventory scores did not significantly differ between groups. Limitations of this study included the use of a small sample of nonclinical patients, short followup, post-randomization withdrawals that did not contribute data to the analysis, and the unclear clinical significance of a decreased anxiety inventory score.

Single-Pulse Transcranial Magnetic Stimulation (sTMS)

Transcranial magnetic stimulation has established treatment protocols and is considered a safe modality for use in the treatment of psychiatric disorders, sTMS was first assessed for the feasibility, tolerability, and patient acceptability for migraine prevention in adolescents through an open-label pilot study in 2018 (Irwin, et al.). The study was small, with only 21 participants enrolled. Participants used sTMS twice daily as a preventative measure, and followed with additional pulses for any acute episodes. A four-week run-in period was followed by a 12-week period of sTMS treatment. The authors concluded that sTMS proved feasible and acceptable, but that device compliance was a challenge for adolescents, related to a 15-minute delay between pulses particularly on school days. The delay requirement was subsequently dropped from the study. The study completion rate was only 31% but increased to 88% following the protocol change. Participants used the device preventively an average of 22 to 24 days over a 28-day period of time. There were no serious adverse events. Larger, long-term higher-quality trials with established stimulation parameters are needed to determine if the use of the technology benefits the net health outcome of individuals with migraine.

Peripheral Magnetic Stimulation Peripheral magnetic stimulation differs from electrical stimulation in that it does not require electrical currents to pass through skin and tissues. The magnetic field is believed to cause ion movement and stimulation of axons, potentially impacting cortical excitability, however, there have been no definitive conclusions regarding the mechanism of action, or creation of a standard protocol for treatment delivery. While preliminary data show that peripheral magnetic stimulation has limited complications, additional well-designed comparative studies with established protocols are needed to determine the overall efficacy and impact on health outcomes.

Transcutaneous Vagus Nerve Stimulation (tVNS)

The evidence for tVNS stimulation in individuals who have epilepsy, depression, schizophrenia, headache, or impaired glucose tolerance includes at least one randomized controlled trial and case series for some of the conditions. The RCTs are small and have various methodologic problems. Definitive efficacy of tVNS in improving outcomes among patients has not been demonstrated. The evidence is insufficient to determine the effects of the technology on health outcomes.

Auricular Electrical Stimulation

Kovacic et al. (2017) conducted an RCT comparing the Neuro-Stim PENFS device with a sham device in adolescent patients with abdominal pain-related functional gastrointestinal disorders including IBS. Patients 11 to 18 years of age with abdominal pain (pain score ≥ 3 on an 11-point scale) occurring at least twice weekly for at least two (2) months were included. The devices were worn for five (5) days each week for four (4) weeks. Baseline medications were continued except for antispasmodics which were not allowed during the study period. Enrolled patients were primarily female (91%) and White (90%). Pain, as measured on the Pain Frequency-Severity-Duration (PFSD), was the primary outcome. The

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS

Policy Number: 01.01.55

Page: 15 of 23

PFSD scale incorporates several aspects of the pain experience and is generally calculated over 14 days but was modified as a weekly score in this trial with a high composite score of 70. Both "worst pain" and median PFSD composite scores were better with PENFS than placebo. The Symptom Response Scale (-7 to +7 [with negative scores as worse and positive scores as better]) was used to assess the overall symptoms. Although the authors reported statistically significantly improved scores with the Neuro-Stim device at 3 weeks, numerical differences between groups were small. Longer-term pain scores obtained at a median of 9.2 weeks after treatment remained improved from baseline in the active treatment group with a decrease of composite PFSD scores of -8.4 compared with 0.0 in the sham group. Adverse events including ear discomfort and adhesive allergy were similar between groups. The study is limited by the small sample size, the heterogeneous population of gastrointestinal disorders, the lack of bowel habit measurement, and the short duration of follow-up. Krasaelap et al. (2020) evaluated a subgroup of 50 patients with IBS from the Kovacic et al. (2017) RCT. At three (3) weeks there were more responders with the active treatment (response defined as $\geq 30\%$ reduction in worst abdominal pain) than with the sham device. At the extended follow-up (8-12 weeks), the percentage of responders was similar between groups (32% vs. 18%; $p=.33$).

CODES

- Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.
- **CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.**
- Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.
- Code Key: Experimental/Investigational = (E/I), Not medically necessary/appropriate = (NMN)

CPT Codes

Code	Description
64555 (E/I)	Percutaneous implantation of neurostimulator electrode-electrode array; peripheral nerve (excludes sacral nerve)
64575 (E/I)	Open implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)
64585 (E/I)	Revision or removal of peripheral neurostimulator electrode array
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver
64596 (E/I)	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array
64999 (E/I)	Unlisted procedure, nervous system (PNS or PNT using needle[s] or needle electrode[s]),
90867 (*E/I)	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management *E/I when indication is headache or pain
90868 (*E/I)	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management *E/I when indication is headache or pain

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS**Policy Number: 01.01.55****Page: 16 of 23**

90869 (*E/I)	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold re-determination with delivery and management *E/I when indication is headache or pain
97014	Application of a modality to one or more areas; electrical stimulation, unattended (e.g., TENS)
97032	Application of a modality to one or more areas; electrical stimulation (manual), each 15 minutes (e.g., TENS)
97813	Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient
97814	with electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure)
0720T (E/I)	Percutaneous electrical nerve field stimulation, cranial nerves, without implantation (e.g., IB-Stim system)
0766T (E/I)	Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, initial treatment, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; first nerve
0767T (E/I)	Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, initial treatment, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; each additional nerve (List separately in addition to code for primary procedure)
0768T (E/I)	Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, subsequent treatment, including noninvasive electroneurographic localization (nerve conduction localization), when performed; first nerve
0769T (E/I)	Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, subsequent treatment, including noninvasive electroneurographic localization (nerve conduction localization), when performed; each additional nerve (List separately in addition to code for primary procedure)
0783T (E/I)	Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment

*Copyright © 2024 American Medical Association, Chicago, IL***HCPCS Codes**

Code	Description
A4540	Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm
A4541	Monthly supplies for use of device coded at E0733
A4542	Supplies and accessories for external upper limb tremor stimulator of the peripheral nerves of the wrist

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS**Policy Number: 01.01.55****Page: 17 of 23**

A4595	Electrical stimulation supplies, 2 lead, per month, (e.g., TENS, NMES)
A4596	Cranial electrotherapy stimulation (ces) system supplies and accessories, per month
A4630	Replacement batteries, medically necessary, transcutaneous electrical stimulator, owned by patient
C9807 (E/I)	Nerve stimulator, percutaneous, peripheral (e.g., sprint peripheral nerve stimulation system), including electrode and all disposable system components, non-opioid medical device (must be a qualifying Medicare non-opioid medical device for post-surgical pain relief in accordance with section 4135 of the caa, 2023 (<i>effective 01/01/25</i>))
E0720	TENS, two lead, localized stimulation
E0721 (E/I)	Transcutaneous electrical nerve stimulatory, stimulates nerves in the auricular region (<i>effective 10/01/24</i>)
E0730	TENS, four or more leads, for multiple nerve stimulation
E0731	Form-fitting conductive garment for delivery of TENS or NMES (with conductive fibers separated from the patient's skin by layers of fabric).
E0732 (E/I)	Cranial electrotherapy stimulation (ces) system, any type
E0733 (E/I)	Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve
E0734 (E/I)	External upper limb tremor stimulator of the peripheral nerves of the wrist (e.g., Cala Trio)
E0744 (NMN)	Neuromuscular stimulator for scoliosis
E0745 (NMN)	Neuromuscular stimulator, electronic shock unit
E0762 (E/I)	Transcutaneous electrical joint stimulation device system, includes all accessories
E0764 (NMN)	Functional neuromuscular stimulation, transcutaneous stimulation of sequential muscle groups of ambulation with computer control, used for walking by spinal cord injured, entire system, after completion of training program
E0769 (NMN)	Electrical stimulation or electromagnetic wound treatment device, not otherwise classified
E0770 (NMN)	Functional neuromuscular stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified
G0281 (NMN)	Electrical stimulation, (unattended), to one or more areas, for chronic Stage III and Stage IV pressure ulcers, arterial ulcers, diabetic ulcers, and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional care, as part of a therapy plan of care
G0282 (NMN)	Electrical stimulation, (unattended), to one or more areas, for wound care other than described in G0281
G0283 (NMN)	Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care
S8130 (E/I)	Interferential current stimulator, 2 channel

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS**Policy Number: 01.01.55****Page: 18 of 23**

S8131 (E/I)	Interferential current stimulator, 4 channel
-------------	--

ICD10 Codes

Code	Description
E08.40-E08.42	Diabetes mellitus due to underlying condition with diabetic neuropathy (code range)
E09.40-E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy (code range)
E10.40-E10.42	Type 1 diabetes mellitus with diabetic neuropathy (code range)
E11.40-E11.42	Type 2 diabetes mellitus with diabetic neuropathy (code range)
E13.40-E13.42	Other specified diabetes mellitus with diabetic neuropathy (code range)
F9.0-F90.9	Attention deficit hyperactivity disorder (code range)
F10.10-F10.99 (E/I)	Alcohol related disorders (code range)
F11.10-F11.99 (E/I)	Opioid related disorders (code range)
F12.10-F12.99 (E/I)	Cannabis related disorders (code range)
F13.10-F13.99 (E/I)	Sedative, hypnotic, or anxiolytic related disorders (code range)
F14.10-F14.99 (E/I)	Cocaine related disorders (code range)
F15.10-F15.99 (E/I)	Other stimulant related disorders (code range)
F16.10-F16.99 (E/I)	Hallucinogen related disorders (code range)
F17.200-F17.299 (E/I)	Nicotine dependence (code range)
F18.10-F18.99 (E/I)	Inhalant related disorders (code range)
F19.10-F19.99 (E/I)	Other psychoactive substance related disorders (code range)
G43.001-G43.019	Migraine without aura (code range)
G43.101-G43.419	Polyneuropathy in diseases classified elsewhere
G43.701-G43.719	Sequelae of inflammatory polyneuropathy (code range)
G43.B0-G43.B1	Chronic pain, not elsewhere classified (code range)
G43.801-G43.919	Chronic pain syndrome
G44.1	Complex regional pain syndrome I (code range)
G44.201-G44.209	Polyosteoarthritis (code range)
G44.211-G44.219	Osteoarthritis of hip (code range)
G44.221-G44.229	Osteoarthritis of knee (code range)
G44.301-G44.309	Osteoarthritis of first carpometacarpal joint (code range)
G44.321-G44.329	Osteoarthritis, shoulder, arm and hand (code range)
G46.0-G46.8 (NMN)	Pain in joint (code range)
G50.0-G50.9	Systemic sclerosis with polyneuropathy
G51.2-G51.9	Fusion of spine, lumbosacral region

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS**Policy Number: 01.01.55****Page: 19 of 23**

Code	Description
G56.00-G56.03	Fusion of spine, sacral and sacrococcygeal region
H92.01-H92.09	Otalgia (code range)
I67.2 (NMN)	Cerebral atherosclerosis
I67.81-I67.82 (NMN)	Other specified cerebrovascular diseases (code range)
I67.89 (NMN)	Other cerebrovascular disease
I67.9 (NMN)	Cerebrovascular disease, unspecified
I68.0 (NMN)	Cerebral amyloid angiopathy
I68.8 (NMN)	Other cerebrovascular disorders in diseases classified elsewhere
K58.0-K58.9 (E/I)	Irritable bowel syndrome (code range)
K91.0	Vomiting following gastrointestinal surgery
M15.0-M15.9	Polyosteoarthritis (code range)
M16.0-M16.9	Osteoarthritis of hip (code range)
M17.0-M17.9	Osteoarthritis of knee (code range)
M18.0-M18.9	Osteoarthritis of first carpometacarpal joint (code range)
M19.011-M19.079	Primary osteoarthritis (code range)
M19.111-M19.179	Post-traumatic osteoarthritis (code range)
M19.211-M19.279	Secondary osteoarthritis (code range)
M19.90-M19.93	Osteoarthritis, unspecified site (code range)
M25.50-M25.579	Pain in joint (code range)
M26.621-M26.629	Arthralgia of temporomandibular joint (code range)
M43.26-M43.28	Fusion of spine (code range)
M43.8x6-M43.8x9	Other specified deforming dorsopathies (code range)
M51.16-M51.17	Intervertebral disc disorders with radiculopathy (code range)
M53.1	Cervicobrachial syndrome
M53.2x7	Spinal instabilities, lumbosacral region
M53.2x8	Spinal instabilities, sacral and sacrococcygeal region
M53.3	Sacrococcygeal disorders, not elsewhere classified
M53.86-M53.88	Other specified dorsopathies (code range)
M53.9	Dorsopathy, unspecified
M54.06-M54.09	Panniculitis affecting regions of neck and back (code range)
M54.16-M54.18	Radiculopathy (code range)
M54.30-M54.32	Sciatica (code range)

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS**Policy Number: 01.01.55****Page: 20 of 23**

Code	Description
M54.40-M54.42	Lumbago with sciatica (code range)
M54.5	Low back pain
M60.80-M60.9	Other myositis (code range)
M62.830	Muscle spasm of back
M77.10-M77.12	Lateral epicondylitis (code range)
M79.0	Rheumatism, unspecified
M79.10-M79.18	Myalgia (code range)
M79.2	Neuralgia and neuritis, unspecified
M79.601-M79.676	Pain in limb, hand, foot, fingers and toes (code range)
R10.0-R10.9	Abdominal and pelvic pain (code range)
R51.0-R51.9	Headache (code range)
R52	Pain, unspecified

REFERENCES

*Ahn H, et al. Feasibility and efficacy of remotely supervised cranial electrical stimulation for pain in older adults with knee osteoarthritis: a randomized controlled pilot study. J Clin Neurosci 2020 July;77:128-133.

Alam MD & Chen JDZ. Non-invasive neuromodulation: an emerging intervention for visceral pain in gastrointestinal disorders. Bioelectronic Medicine 2023; 27(9): 1-27.

Allen CB, et al. Do electrical stimulation devices reduce pain and improve function? A comparative review. Pain Ther 2023; 12:1339-1354.

*Barclay TH, et al. A clinical trial of cranial electrotherapy stimulation for anxiety and comorbid depression. Journal of Affective Disorders 2014;164:171-177.

*Beltran-Alacreu H, et al. Percutaneous versus transcutaneous electrical nerve stimulation for the treatment of musculoskeletal pain. A systematic review and meta-analysis. Pain Med 2022 Aug 01; 23(8): 1387-1400.

*Brosseau L, et al. Transcutaneous electrical nerve stimulation (TENS) for the treatment of rheumatoid arthritis in the hand (Review). Cochrane Database Syst Rev 2010;(7): CD004377.

*Boldt I, et al. Non-pharmacological interventions for chronic pain in people with spinal cord injury. Cochrane Database Syst Rev. 2014;11:CD009177.

*Buchmuller A, et al. Value of TENS for relief of chronic low back pain with or without radicular pain. Eur J Pain 2012 May;16(5):656-65.

*Chutkan, NB et al. Evidence-based clinical guidelines for multidisciplinary spine care: diagnosis and treatment of low back pain. North American Spine Society 2020:
<https://www.spine.org/Portals/0/assets/downloads/ResearchClinicalCare/Guidelines/LowBackPain.pdf> accessed 10/31/24.

Chogle A, et al. A multicenter registry study on percutaneous electrical nerve field stimulation for pediatric disorders of gut-brain interaction. J Pediatr Gastroenterol Nutr 2024 Apr;78(4):817-826.

Dantas et al. Gait training with functional electrical stimulation improves mobility in people post-stroke. International Journal of Environmental Research and Public Health 2023 May; 20(9):5728.

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS

Policy Number: 01.01.55

Page: 21 of 23

- *Dowswell T et al. Transcutaneous electrical nerve stimulation (TENS) for pain relief in labour. *Cochrane Database Syst Rev* 2009;(2):CD007214.
- *Dubinsky RM , et al. Assessment: efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review). Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. *Neurology* 2010;74:173–6.
- *Gilligan C, et al. An implantable restorative-neurostimulator for refractory mechanical chronic low back pain: a randomized sham-controlled clinical trial. *Pain* 2021 Oct 21;162(10): 2486-2498.
- *Gilligan C, et al. Long-term outcomes of restorative neurostimulation in patients with refractory chronic low back pain secondary to multifidus dysfunction: two-year results of the ReActiv8-B pivotal trial. *Neuromodulation* 2023 Jan; 26(1): 87-97.
- *Gilligan C, et al. Three-year durability of restorative neurostimulation effectiveness in patients with chronic low back pain and multifidus muscle dysfunction. *Neuromodulation* 2023 Jan; 26(1): 98-108.
- *Gillmore CA, et al. Treatment of chronic axial back pain with 60-day percutaneous medial branch PNS: Primary end point results from a prospective, multicenter study. *Pain Practice* 2021; 21:877-889.
- Hershey AD, et al. Remote electrical neuromodulation for acute treatment of migraine in adolescents. *Headache* 2020 Nov 16; 61:310-317.
- *Hurlow A, et al. Transcutaneous electrical nerve stimulation (TENS) for cancer pain in adults. *Cochrane Database Syst Rev* 2012;(3):CD 006276.
- *Hussein HM, et al. A systematic review and meta-analysis investigating the pain-relieving effect of interferential current on musculoskeletal pain. *Am J Phys Med Rehabil* 2022 July;101(7)624-633.
- *Isaacson SH, et al. Prospective home-use study on non-invasive neuromodulation therapy for essential tremor. *Tremor Other Hyperkinet Mov* 2020 Aug 14; 10: 29.
- *Johnson MI, et al. Transcutaneous electrical nerve stimulation (TENS) for phantom pain and stump pain following amputation in adults. *Cochrane Database Syst Rev* 2015 Aug 18;8:CD007264.
- *Kamo T, et al. Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke. *Cochrane Database of Syst Rev* 2022;9:CD011968.
- *Khadilkar A, et al. Transcutaneous electrical nerve stimulation (TENS) versus placebo for chronic low-back pain. *Cochrane Database Syst Rev* 2013;(2):CD003008.
- *Kim, et al. Effects of cranial electrotherapy stimulation with novel in-ear electrodes on anxiety and resting-state brain activity: A randomized double-blind placebo-controlled trial. *J Affect Disord* 2021 Dec 01;295:856-864.
- *Krasaelap A, et al. Efficacy of auricular neurostimulation in adolescents with irritable bowel syndrome in a randomized, double-blind trial. *Clin Gastroenterol Hepatol* 2020 Aug; 18(9):1987-1994.
- *Kroeling P, et al. Electrotherapy for neck pain. *Cochrane Database Syst Rev* 2013;(8):CD004251.
- *Li S, et al. Electromagnetic fields for treating osteoarthritis. *Cochrane Database Syst Rev* 2013;12:CD003523.
- *Kovacic K, et al. Neurostimulation for abdominal pain-related functional gastrointestinal disorders in adolescents: a randomised, double-blind, sham-controlled trial. *Lancet Gastroenterol Hepatol* 2017 Oct;2(10):727-737.
- *Lim YH, et al. Effects of repetitive peripheral magnetic stimulation on patients with acute low back pain: A pilot study. *Annals of Rehab Medicine* 2018;42(2)229-238.
- *Loh J, et al. The use of transcutaneous electrical nerve stimulation (TENS) in a major cancer center for the treatment of severe cancer-related pain and associated disability. *Pain Med* 2013 Feb 25.

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS

Policy Number: 01.01.55

Page: 22 of 23

*Martimbianco ALC, et al. Transcutaneous electrical nerve stimulation (TENS) for chronic neck pain. *Cochrane Database Syst Rev* 2019 Dec 12;12(12):CD011927.

*Magis D, et al. Safety and patients' satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly(R) device in headache treatment: a survey of 2,313 headache sufferers in the general population. *J Headache Pain* 2013;14:95.

McGough JJ, et al. Double-Blind, Sham-Controlled, Pilot Study of Trigeminal Nerve Stimulation for Attention-Deficit/Hyperactivity Disorder. *J Am Acad Child Adolesc Psychiatry* 2019;58(4):403–411.

Mori N, et al. Analgesic effects of repetitive transcranial magnetic stimulation at different stimulus parameters for neuropathic pain: a randomized study. *Neuromodulation* 2022 Jun;25(4):520-527.

*Plaza-Manzano G, et al. Effectiveness of percutaneous electrical nerve stimulation for musculoskeletal pain: A systematic review and meta-analysis. *Eur J Pain* Jul 2020;24(6):1023-1044.

*Gibson, W, et al. Transcutaneous electrical nerve stimulation (TENS) for chronic pain. *Cochrane Database Syst Rev* 2019;(4):CD011890.

Gil-Lopez, et al. External trigeminal nerve stimulation for drug resistant epilepsy: A randomized controlled trial. *Brain Stimulation* 2020 Jun;(13):1245-1253.

*Irwin SL, et al. Transcranial magnetic stimulation for migraine prevention in adolescents: a pilot open-label study. *Headache* 2018 May;58(5):724-731.

*Pahwa R, et al. An acute randomized controlled trial of noninvasive peripheral nerve stimulation in essential tremor. *Neuromodulation* 2019; 22:537-545.

*Pelland L, et al. Electrical stimulation for the treatment of rheumatoid arthritis (Review). *Cochrane Database Syst Rev* 2010;(7): CD003687.

*Rutjes AWS, et al. Transcutaneous electrostimulation for osteoarthritis of the knee. *Cochrane Database Syst Rev* 2010;(1): CD002823.

*Schoenen J, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. *Neurology* 2013;80(8):697-704.

*Simpson PM, et al. Transcutaneous electrical nerve stimulation for relieving acute pain in the prehospital setting: a systematic review and meta-analysis of randomized-controlled trials. *Eur J Emerg Med* Feb 2014;21(1):10-17.

*Strand N, et al. Evidence-based clinical guidelines from the American Society of Pain and Neuroscience for the use of implantable peripheral nerve stimulation in the treatment of chronic pain. *Journal of Pain Research* 2022 Aug;15:2483-2504.

*Vance CG, et al. Effects of transcutaneous electrical nerve stimulation on pain, pain sensitivity and function in people with knee osteoarthritis: a randomized controlled trial. *Phys Ther* 2012 Jul;92(7):898-910.

*van Middlekoop M, et al. A systematic review of the effectiveness of physical and rehabilitation interventions for chronic non-specific low back pain. *Eur Spine J* 2011 Jan;(1):19-39.

*Walsh DM et al. Transcutaneous electrical nerve stimulation for acute pain. *Cochrane Database Syst Rev* 2009;(2):CD006142.

*Weiner DK, et al. Efficacy of percutaneous electrical nerve stimulation and therapeutic exercise for older adults with chronic low back pain: a randomized controlled trial. *Pain* 2008 Nov;140(2):344-357.

*White PF et al. Percutaneous Neuromodulation therapy: does the location of electrical stimulation effect the acute analgesic response? *Anesth Analg* 2000 Oct; 91:949-954.

*Yarnitsky D, et al. Remote electrical neuromodulation (REN) relieves acute migraine: a randomized, double-blind, placebo-controlled, multicenter trial. *Headache J Head Face Pain* 2019;59:1240–52.

Medical Policy: ELECTRICAL STIMULATION FOR PAIN AND OTHER MEDICAL CONDITIONS

Policy Number: 01.01.55

Page: 23 of 23

*Zizic TM et al. The treatment of osteoarthritis of the knee with pulsed electrical stimulation. J Rheumatol 1995 Sep;22(9):1757-1761.

KEY WORDS

Bionicare, Electrical nerve stimulation, Electrotherapy, IFS, Percutaneous neuromodulation therapy, Transcutaneous nerve stimulation, Neuromodulation, Remote electrical neuromodulation, Nerivio, Cranial electrical stimulation, Alpha Stim, Trigeminal Nerve Stimulation, Peripheral magnetic stimulation.

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

There is currently a National Coverage Determination (NCD) and a Local Coverage Determination (LCD) for TENS units. Please refer to the following NCD and LCD websites for Medicare Members:

There is currently a Local Coverage Determination (LCD L33802) for Transcutaneous Electrical Nerve Stimulators:

https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33802&ver=35&CtrctrSelected=137*1&Ctrctr=137&s=41&DocType=Active&bc=AggAAAIAGAAA&= accessed 10/30/24.

There is currently a National Coverage Determination (NCD) for TENS units for Acute Post-Operative Pain (NCD 10.2).

Please refer to the following NCD website for Medicare Members: <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=145&ncdver=2&bc=AAAAGAAAAAAAA&> accessed 10/30/24.

There is currently a National Coverage Determination (NCD) for TENS units for Chronic Low Back Pain (NCD 160.27).

Please refer to the following NCD website for Medicare Members: <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=354&ncdver=1&bc=AgAAgAAAAAAAAAAA%3d%3d&> accessed 10/30/24.

There is currently a National Coverage Determination (NCD#160.12) for Neuromuscular Electrical Stimulation (NMES).

Please refer to the following NCD website for Medicare Members: <http://www.cms.gov/medicare-coverage-database/details/ncddetails.aspx?NCDId=175&ncdver=2&bc=BAABAAAAAAAA&> accessed 10/30/24.